Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of patient deaths in other trials for the modality and sent the company’s stock tumbling in pre-market trading.